TrialNeurology(R) neuroimmunology & neuroinflammation2023

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.

Sarah A Laurent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.